An updated patent review of IDO1 inhibitors for cancer (2018–2022)-Reference-Cited by-同舟云学术

An updated patent review of IDO1 inhibitors for cancer (2018–2022)

Published:2022-11-02 Issue:11 Volume:32 Page:1145-1159
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Wang Peng-Fei¹,Yang Li-Qiang¹,Shi Zhao-Hang¹,Li Xue-Min¹,Qiu Han-Yue¹

Affiliation:

1. Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, Chongqing, People’s Republic of China

Funder

Fundamental Research Funds for the Central Universities

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2022.2151894

Reference104 articles.

1. The future of cancer immunotherapy: microenvironment-targeting combinations

2. A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future

3. Cancer immunotherapy comes of age

4. Advances in the discovery and development of selective heme-displacing IDO1 inhibitors

5. IDO1 in cancer: a Gemini of immune checkpoints

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer;Cell Death & Disease;2024-02-01

2. Membrane Localization and Phosphorylation of Indoleamine 2,3-Dioxygenase 2 (IDO2) in A549 Human Lung Adenocarcinoma Cells: First Steps in Exploring Its Signaling Function;International Journal of Molecular Sciences;2023-11-12

3. Developing reliable classification of dual IDO1/TDO inhibitors using data fusion and majority voting;Journal of Biomolecular Structure and Dynamics;2023-11-03

4. Prediction of IDO1 Inhibitors by a Fingerprint‐Based Stacking Ensemble Model Named IDO1Stack;ChemMedChem;2023-06-30

5. PROTACs: Novel tools for improving immunotherapy in cancer;Cancer Letters;2023-04